Clinical Trial Update: Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated the combination of venetoclax and selinexor in relapsed or refractory high-risk hematologic malignancies, including diffuse large B…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Venclexta (venetoclax)
• XPOVIO (selinexor)

Snippet

Sponsor: Sanjay Mohan | Conditions: Diffuse Large B-cell Lymphoma, Acute Myeloid Leukemia | Phase 1 | Status: COMPLETED